Inventiva SA (IVA)

NASDAQ: IVA · IEX Real-Time Price · USD
8.85
0.05 (0.56%)
May 16, 2022 4:00 PM EDT - Market closed
Market Cap361.73M
Revenue (ttm)8.50M
Net Income (ttm)-49.64M
Shares Out40.87M
EPS (ttm)-1.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,836
Open9.00
Previous Close8.80
Day's Range8.85 - 9.10
52-Week Range8.00 - 16.93
Beta0.95
AnalystsBuy
Price Target31.69 (+258.1%)
Earnings DateMar 3, 2022

About IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. Th...

IndustryBiotechnology
IPO DateJul 10, 2020
CEOFrederic Cren
Employees101
Stock ExchangeNASDAQ
Ticker SymbolIVA
Full Company Profile

Financial Performance

In 2021, Inventiva's revenue was $8.50 million, an increase of 61.52% compared to the previous year's $5.26 million. Losses were -$49.64 million, 47.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for IVA stock is "Buy." The 12-month stock price forecast is 31.69, which is an increase of 258.08% from the latest price.

Price Target
$31.69
(258.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver

Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small...

1 month ago - GlobeNewsWire

How Much Upside is Left in Inventiva S.A. Sponsored ADR (IVA)?

The average of price targets set by Wall Street analysts indicates a potential upside of 166.4% in Inventiva S.A. Sponsored ADR (IVA).

1 month ago - Zacks Investment Research

Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F

Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...

2 months ago - GlobeNewsWire

Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin i...

FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed

2 months ago - GlobeNewsWire

Inventiva announces participation at several conferences in March 2022

Daix (France), Long Island City (New York, United States), March 1, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small...

2 months ago - GlobeNewsWire

Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results

Daix (France), Long Island City (New York, United States), February 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...

2 months ago - GlobeNewsWire

Wall Street Analysts Think Inventiva S.A. Sponsored ADR (IVA) Could Surge 153%: Read This Before Placing a Bet

The consensus price target hints at a 152.7% upside potential for Inventiva S.A. Sponsored ADR (IVA).

2 months ago - Zacks Investment Research

Inventiva reports cash position and revenues for Full-Year 2021

Daix (France), Long Island City (New York, United States), February 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...

3 months ago - GlobeNewsWire

Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation

Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm...

Other symbols:ABBV
3 months ago - GlobeNewsWire

Inventiva announces participation at several conferences in January and February 2022

Daix (France), Long Island City (New York, United States) , January 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...

3 months ago - GlobeNewsWire

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule th...

4 months ago - GlobeNewsWire

Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule t...

5 months ago - GlobeNewsWire

Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor

Inventiva (NASDAQ: IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The assessment of lanifibranor on cardiac repol...

5 months ago - Benzinga

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

Daix (France), Long Island City (New York, United States) , December 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...

5 months ago - GlobeNewsWire

Inventiva reports 2021 Third Quarter Financial Information

Daix (France), Long Island City (New York, United States), November 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s...

6 months ago - GlobeNewsWire

Fast Track Status Expanded For Inventiva's NASH Treatment

The FDA has decided that the Fast Track designation previously granted to Inventiva SA's (NASDAQ: IVA) lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis. The dec...

7 months ago - Benzinga

Inventiva announces the implementation of an At-The-Market program in the United States

Daix (France), August 2, 2021 (GLOBE NEWSWIRE) – Inventiva S.A. (NASDAQ: IVA – EURONEXT PARIS: IVA) (the “Company”), a clinical-stage biotechnological company focused on the development of oral small mo...

9 months ago - GlobeNewsWire